|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-4-21
|
|
pubmed:abstractText |
The response of colorectal tumours to chemotherapy is highly variable. Preclinical work has shown that the Kirsten ras (KRAS) oncogene sensitizes colorectal tumour cells to oxaliplatin and capecitabine in a wild-type tumour suppressor p53 (TP53)-dependent manner. Therefore, whether or not the combined mutation status of KRAS and TP53 could predict response to chemotherapy in metastatic colorectal cancer was tested.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/KRAS protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/TP53 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab,
http://linkedlifedata.com/resource/pubmed/chemical/capecitabine,
http://linkedlifedata.com/resource/pubmed/chemical/cetuximab,
http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin,
http://linkedlifedata.com/resource/pubmed/chemical/ras Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1791-7530
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
31
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1379-85
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21508389-Antibodies, Monoclonal,
pubmed-meshheading:21508389-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21508389-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21508389-Clinical Trials, Phase III as Topic,
pubmed-meshheading:21508389-Colorectal Neoplasms,
pubmed-meshheading:21508389-DNA, Neoplasm,
pubmed-meshheading:21508389-Deoxycytidine,
pubmed-meshheading:21508389-Fluorouracil,
pubmed-meshheading:21508389-Humans,
pubmed-meshheading:21508389-Mutation,
pubmed-meshheading:21508389-Organoplatinum Compounds,
pubmed-meshheading:21508389-Polymerase Chain Reaction,
pubmed-meshheading:21508389-Prognosis,
pubmed-meshheading:21508389-Proto-Oncogene Proteins,
pubmed-meshheading:21508389-Survival Rate,
pubmed-meshheading:21508389-Tumor Suppressor Protein p53,
pubmed-meshheading:21508389-ras Proteins
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.
|
|
pubmed:affiliation |
Department of Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, the Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
